Heart enzyme levels tracked after updated mRNA shot in 1,000 youth

NCT ID NCT06634797

Completed Knowledge-focused Sponsor: ModernaTX, Inc. Source: ClinicalTrials.gov ↗

First seen Feb 04, 2026 · Last updated Jun 19, 2026 · Updated 24 times

Summary

This completed Phase 4 study tested whether an updated COVID-19 vaccine (mRNA-1273.712) affects heart muscle in healthy people aged 12 to 30. Researchers measured a heart enzyme called troponin in 1,000 participants who received either the vaccine or a placebo. The goal was to see if the vaccine causes any temporary heart stress, helping to understand its safety profile in younger populations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Velocity Clinical Research, Abilene

Abilene, Texas, 79606, United States
Velocity Clinical Research, Albuquerque

Albuquerque, New Mexico, 87107, United States
Velocity Clinical Research, Anderson

Anderson, South Carolina, 29621, United States
Velocity Clinical Research, Banning

San Bernardino, California, 82408, United States
Velocity Clinical Research, Boise

Meridian, Idaho, 83642, United States
Velocity Clinical Research, Cincinnati

Cincinnati, Ohio, 45246, United States
Velocity Clinical Research, Cincinnati, Blue Ash

Blue Ash, Ohio, 45242, United States
Velocity Clinical Research, Cleveland

Beachwood, Ohio, 44122, United States
Velocity Clinical Research, Covington

Covington, Louisiana, 70433, United States
Velocity Clinical Research, Durham

Durham, North Carolina, 27701, United States
Velocity Clinical Research, Grand Island

Grand Island, Nebraska, 68803, United States
Velocity Clinical Research, Gulfport

Gulfport, Mississippi, 39503, United States
Velocity Clinical Research, Huntington Park

Huntington Park, California, 90255, United States
Velocity Clinical Research, Lafayette

Lafayette, Louisiana, 70508, United States
Velocity Clinical Research, Lincoln

Lincoln, Nebraska, 68510, United States
Velocity Clinical Research, New Orleans

New Orleans, Louisiana, 70119, United States
Velocity Clinical Research, Omaha

Omaha, Nebraska, 68134, United States
Velocity Clinical Research, Phoenix

Phoenix, Arizona, 85006, United States
Velocity Clinical Research, Salt Lake City

West Jordan, Utah, 84088, United States
Velocity Clinical Research, San Diego

La Mesa, California, 91942, United States
Velocity Clinical Research, Savannah

Savannah, Georgia, 31406, United States
Velocity Clinical Research, Syracuse

East Syracuse, New York, 13057, United States
Velocity Clinical Research, Valparaiso

Valparaiso, Indiana, 46383, United States
Velocity Clinical Research, Washington DC

Washington D.C., District of Columbia, 20016, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mRNA-1273.712 vaccine

What this could lead to

If successful, this could provide reassurance that the updated mRNA vaccine does not cause heart muscle injury in young people.

What could go wrong

This is a completed safety study, not designed to prove the vaccine works. Results may not apply to other age groups or vaccine types.

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS HEALTHY VOLUNTEERS